Clinical Trial

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-11-25; most recent amendment 2024-06-22.
Trial Details
NCT Number NCT03755739
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer, Head and Neck Cancer, Pancreas Cancer, Ovarian Cancer, Colo-rectal Cancer +2 more
Enrollment 200 participants
Start Date 2018-11-01
Primary Completion 2033-11-01 (estimated)
Study Completion 2036-11-01 (estimated)
Updated on ClinicalTrials.gov 2024-06-25